• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病生活质量简化问卷。

Shortened questionnaire on quality of life for inflammatory bowel disease.

作者信息

Alcalá M J, Casellas F, Fontanet G, Prieto L, Malagelada J-R

机构信息

Hospital Universitari Vall d'Hebron, Barcelona, Spain.

出版信息

Inflamm Bowel Dis. 2004 Jul;10(4):383-91. doi: 10.1097/00054725-200407000-00009.

DOI:10.1097/00054725-200407000-00009
PMID:15475746
Abstract

Questionnaires for measuring quality of life in patients with inflammatory bowel disease usually include a large number of items and are time-consuming for both administration and interpretation. Our aim was to elaborate and validate a short quality-of-life questionnaire with the most representative items from the Spanish version of the 36-item Inflammatory Bowel Disease Questionnaire (IBDQ-36) using the Rasch analysis. The responses to 311 IBDQ-36 questionnaires from 167 patients with ulcerative colitis (UC) and 144 with Crohn's disease (CD) were analyzed. IBDQ-36 was shortened with successive Rasch analyses until all the remaining items showed acceptable separation and goodness-of-fit properties. Validation of the short questionnaire was studied in a new group of 125 patients by determining its validity and reliability. A 9-item short questionnaire was obtained (IBDQ-9). Its correlation with IBDQ-36 was excellent (r = 0.91). Correlation between IBDQ-9 and clinical indices of activity was statistically significant in UC (r = 0.70) and CD (r= 0.70). IBDQ-9 score discriminates adequately between patients in clinical remission or relapse (P < 0.01). Sensitivity to change was determined in 14 patients who improved clinically, showing significant IBDQ-9 changes between both determinations (P < 0.01), with an effect size of -2.67 in UC and -5.29 in CD. IBDQ-9 was also homogeneous, with a Cronbach's alpha of 0.95 in UC and 0.91 in CD. In 35-clinically stable patients, test-retest reliability was good, with a statistically-significant correlation between both questionnaires (r = 0.76 in UC and 0.86 in CD, P < 0.01) and an intraclass correlation coefficient of 0.82 in UC and 0.84 in CD. In conclusion, a short and valid questionnaire to measure quality of life in patients with inflammatory bowel disease was obtained using a new measurement model. Its use should facilitate comprehension of the impact of inflammatory bowel disease.

摘要

用于测量炎症性肠病患者生活质量的问卷通常包含大量项目,管理和解读都很耗时。我们的目的是使用拉施分析,从36项炎症性肠病问卷(IBDQ - 36)的西班牙文版本中精心挑选出最具代表性的项目,编制并验证一份简短的生活质量问卷。分析了167例溃疡性结肠炎(UC)患者和144例克罗恩病(CD)患者对311份IBDQ - 36问卷的回答。通过连续的拉施分析对IBDQ - 36进行缩短,直到所有剩余项目都显示出可接受的区分度和拟合优度。通过确定其有效性和可靠性,在一组125名新患者中研究了简短问卷的有效性。获得了一份9项简短问卷(IBDQ - 9)。它与IBDQ - 36的相关性极佳(r = 0.91)。IBDQ - 9与UC(r = 0.70)和CD(r = 0.70)的临床活动指标之间的相关性具有统计学意义。IBDQ - 9评分能够充分区分临床缓解或复发的患者(P < 0.01)。在14例临床症状改善的患者中确定了对变化的敏感性,两次测定之间IBDQ - 9有显著变化(P < 0.01),UC中的效应大小为 - 2.67,CD中的效应大小为 - 5.29。IBDQ - 9也具有同质性,UC中的克朗巴哈系数为0.95,CD中的为0.91。在35例临床稳定的患者中,重测信度良好,两份问卷之间具有统计学意义的相关性(UC中r = 0.76,CD中r = 0.86,P < 0.01),UC中的组内相关系数为0.82,CD中的为0.84。总之,使用一种新的测量模型获得了一份简短且有效的问卷,用于测量炎症性肠病患者的生活质量。其使用应有助于理解炎症性肠病的影响。

相似文献

1
Shortened questionnaire on quality of life for inflammatory bowel disease.炎症性肠病生活质量简化问卷。
Inflamm Bowel Dis. 2004 Jul;10(4):383-91. doi: 10.1097/00054725-200407000-00009.
2
Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn's disease.中国大陆版炎症性肠病问卷(IBDQ)用于溃疡性结肠炎和克罗恩病的效度验证。
Inflamm Bowel Dis. 2007 Jul;13(7):903-10. doi: 10.1002/ibd.20128.
3
[Spanish translation, adaptation, and validation of the 32-item questionnaire on quality of life for inflammatory bowel disease(IBDQ-32)].[32项炎症性肠病生活质量问卷(IBDQ - 32)的西班牙语翻译、改编及验证]
Rev Esp Enferm Dig. 2007 Sep;99(9):511-9. doi: 10.4321/s1130-01082007000900006.
4
Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire.使用简短问卷评估疾病活动对炎症性肠病患者生活质量的影响。
Am J Gastroenterol. 2004 Mar;99(3):457-61. doi: 10.1111/j.1572-0241.2004.04071.x.
5
The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease?激励研究:溃疡性结肠炎和克罗恩病的痛苦患者中,不同人格特质与疾病特异性生活质量(IBDQ)有关吗?
Inflamm Bowel Dis. 2008 May;14(5):680-6. doi: 10.1002/ibd.20367.
6
Validation of the spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease.炎症性肠病问卷西班牙语版在溃疡性结肠炎和克罗恩病方面的验证
Digestion. 1999;60(3):274-80. doi: 10.1159/000007670.
7
Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn's disease.溃疡性结肠炎和克罗恩病炎症性肠病问卷土耳其语版的验证和可靠性。
Turk J Gastroenterol. 2020 Aug;31(8):566-572. doi: 10.5152/tjg.2020.19553.
8
Development and Validation of a Questionnaire to Assess the Quality of Life in Patients with Inflammatory Bowel Disease in Mainland China.中国大陆炎症性肠病患者生活质量评估问卷的研制与验证
Inflamm Bowel Dis. 2017 Mar;23(3):431-439. doi: 10.1097/MIB.0000000000001024.
9
Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease.IBDQ-32 问卷在墨西哥炎症性肠病患者中的有效性和可靠性。
Gastroenterol Hepatol. 2021 Dec;44(10):711-718. doi: 10.1016/j.gastrohep.2021.03.002. Epub 2021 Apr 16.
10
The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial.《简短炎症性肠病问卷:用于社区医生管理炎症性肠病的生活质量工具》。CCRPT研究人员。加拿大克罗恩病复发预防试验。
Am J Gastroenterol. 1996 Aug;91(8):1571-8.

引用本文的文献

1
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.缓解期炎症性肠病患者停用抗肿瘤坏死因子:GETECCU的一项随机安慰剂对照临床试验
Gut. 2025 Feb 6;74(3):387-396. doi: 10.1136/gutjnl-2024-333385.
2
Clinical Education: Psychosocial Assessment and Treatment Planning for Patients with Inflammatory Bowel Disease.临床教育:炎症性肠病患者的心理社会评估与治疗计划。
J Clin Psychol Med Settings. 2024 Jun;31(2):237-244. doi: 10.1007/s10880-024-10006-8. Epub 2024 May 11.
3
A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process.
炎症性肠病核心结局集:通过国际多利益相关者共识过程制定和推荐在临床实践中的实施
J Crohns Colitis. 2024 Oct 15;18(10):1583-1595. doi: 10.1093/ecco-jcc/jjad195.
4
Patient-Reported Outcomes in Colorectal Surgery.结直肠手术中患者报告的结局
Clin Colon Rectal Surg. 2023 Feb 8;36(4):240-251. doi: 10.1055/s-0043-1761607. eCollection 2023 Jul.
5
Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers.我们是否已经准备好进行炎症性肠病的远程监测了?对进展、促成因素和障碍的回顾。
World J Gastroenterol. 2023 Feb 21;29(7):1139-1156. doi: 10.3748/wjg.v29.i7.1139.
6
Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals.磷酸甘露糖变位酶 2 先天性糖基化障碍(PMM2-CDG)患者报告结局:倾听患者和医疗保健专业人员的心声。
Orphanet J Rare Dis. 2022 Oct 29;17(1):398. doi: 10.1186/s13023-022-02551-y.
7
Quality of Life in Inflammatory Bowel Diseases (IBDs) Patients after Surgery.炎症性肠病(IBD)患者手术后的生活质量。
Rev Recent Clin Trials. 2022;17(4):227-239. doi: 10.2174/1574887117666220811143426.
8
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.缓解期炎症性肠病患者停用抗肿瘤坏死因子治疗:一项前瞻性、多中心、随机临床试验的研究方案
Therap Adv Gastroenterol. 2019 Sep 13;12:1756284819874202. doi: 10.1177/1756284819874202. eCollection 2019.
9
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.从每周一次注射40毫克阿达木单抗转换为每两周一次注射80毫克后炎症性肠病患者的偏好和满意度:ADASCAL研究
Therap Adv Gastroenterol. 2021 Nov 24;14:17562848211056157. doi: 10.1177/17562848211056157. eCollection 2021.
10
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.蔗糖铁补充剂治疗对口服铁治疗抵抗的炎症性肠病患者缺铁性贫血。
Nutrients. 2021 May 22;13(6):1770. doi: 10.3390/nu13061770.